D. Boral Capital Reiterates “Buy” Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They presently have a $25.00 target price on the stock.

A number of other equities research analysts have also recently issued reports on HUMA. BTIG Research reissued a “buy” rating and issued a $6.00 price target on shares of Humacyte in a research note on Monday, February 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. Benchmark dropped their target price on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, January 21st. Wall Street Zen downgraded shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Humacyte in a research note on Monday, December 1st. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.14.

Humacyte Price Performance

NASDAQ:HUMA opened at $1.13 on Thursday. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. The company has a 50 day moving average price of $1.06 and a 200-day moving average price of $1.40. Humacyte has a 1-year low of $0.88 and a 1-year high of $3.94. The firm has a market cap of $211.62 million, a price-to-earnings ratio of -4.91 and a beta of 1.93.

Hedge Funds Weigh In On Humacyte

Hedge funds have recently made changes to their positions in the stock. Prudential Financial Inc. acquired a new position in Humacyte during the 2nd quarter worth about $28,000. Financial Advisors Network Inc. purchased a new stake in Humacyte during the second quarter worth about $28,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Humacyte during the second quarter worth about $30,000. Valeo Financial Advisors LLC acquired a new stake in shares of Humacyte during the second quarter worth about $32,000. Finally, Truist Financial Corp purchased a new position in shares of Humacyte in the third quarter valued at approximately $28,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.